This episode dives into how innovative technologies are enabling point-of-care clinical decision support, ensuring patients gain seamless access to potentially life-saving genetic information throughout their healthcare journey.
Rome and Feyi Ayodele, CEO of Cancer IQ explore strategies to break down traditional barriers to patient access that empower primary care physicians (PCPs) and specialists to integrate genetic and genomic insights directly into routine appointments. Discover how digital solutions are transforming patient selection for hereditary cancer testing – including crucial breast cancer risk assessments – and streamlining access to precision medicine. We’ll also uncover how these advancements are fostering a more proactive and equitable healthcare landscape.
Feyi was a speaker at this week’s HLTH Innovation Conference in Las Vegas on Innovations Revolutionizing Oncology, Cancer IQ was named by Time Magazine as One of the World’s Top Healthcare Companies in 2025, a finalist for Fierce Healthcare’s Innovation Awards, and was named as one of Modern Healthcare’s 2024 Innovators.
Key Takeaways:
- Point-of-Care Clinical Decision Support: Understand how digital tools are empowering healthcare providers with real-time access to guidelines to identify patients who would benefit most from genetic testing.
- Democratizing Access: Explore strategies for overcoming geographic and socioeconomic barriers, ensuring equitable access to hereditary cancer testing and precision medicine for all.
- Informed Decision-Making: Discover how digital platforms are facilitating informed conversations between patients and providers about risk assessment, personalized prevention, and genetic testing options.
- Empowering Self-Advocacy: Gain insights into how patients can leverage these technological advancements to become more effective self-advocates for their genetic health.
We help you build the language and confidence to become a more effective self-advocate for precision medicine.
